Comment from Viatris Inc.

Summary: Viatris Inc. supports the Commissioner’s National Priority Voucher (CNPV) Pilot Program as a means to accelerate the review of drugs addressing national health priorities. However, the company requests that the FDA provide clearer guidance on eligibility, selection processes, and regulatory engagement to ensure the program complements existing expedited review mechanisms and is properly resourced.